On June 2, 2017 Progenics Pharmaceuticals, Inc. (Nasdaq:PGNX), an oncology company developing innovative medicines and imaging analytical tools for targeting and treating cancer, reported the presentation of two studies highlighting the use of an automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC) at the 2017 American Society of Clinical Oncology (ASCO) (Free ASCO Whitepaper) Annual Meeting, taking place June 2-6 in Chicago, Illinois (Press release, Progenics Pharmaceuticals, JUN 2, 2017, View Source [SID1234519350]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The vast majority of men with CRPC have bone metastases and bone scans are the standard imaging modality in these patients. Bone scans indirectly assess tumor activity by measuring bone mineral turnover. The bone scan index quantifies the prostate cancer disease burden shown on a bone scan. Employing artificial intelligence, the aBSI automatically calculates the bone scan index. aBSI permits a faster quantitative assessment of tumor burden compared to manual BSI and is highly reproducible

The first study, entitled, "Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC)," will be featured during an oral presentation on June 3rd. This study is the first evaluation of aBSI in a phase 3 study as a prognostic biomarker for survival in patients with bone-metastatic CRPC. The study demonstrated that in these patients, aBSI at baseline was prognostic for overall and disease specific survival (p <0.0001), progression free survival (p =0.0024), radiographic progression-free survival (rPFS) (p =0.0061), and symptomatic skeletal related events (SSEs) (p =0.0068).

"This large scale study highlights the ability of the aBSI to provide clinically meaningful prognostic information to patients with bone-metastatic CRPC, using a quantitative software method to assess the burden of bone metastases," said Andrew Armstrong, MD ScM FACP, Associate Professor of Medicine and Surgery, Associate Director for Clinical Research in Genitourinary Oncology Duke Cancer Institute, Duke University, Durham, NC. "This is the largest study to date of this bone scan index and we demonstrate clinically important outcomes associated with increasing BSI including mortality and symptomatic progression, independent of other known factors."

The second study will be presented at ASCO (Free ASCO Whitepaper) on June 5th as a poster titled "Translating Prostate Cancer Working Group (PCWG) Criteria into a Quantitative Progression Biomarker in Metastatic Castration Resistant Prostate Cancer (mCRPC)". This study demonstrates the utility of automated bone scan indexing to quantitatively assess total tumor burden during the course of disease progression as called for by PCWG2 criteria.

"Historically, assessing treatment effects in prostate cancer has been complicated by the dominance of bone metastases relative to soft tissue disease, making it difficult to accurately assess changes in disease burden over time in patients with mCRPC," said Michael J. Morris, MD of Memorial Sloan Kettering Cancer Center. "There is a significant need for a fully quantitative biomarker to demonstrate treatment response in these patients, and the current data are encouraging that the aBSI reflects clinically relevant changes in bone, and may fulfill this unmet need."



The schedule for the presentations at ASCO (Free ASCO Whitepaper) is as follows:

Date & Time: Saturday, June 3, 2017, 1:15 PM-4:15 PM

Session Title: Genitourinary (Prostate) Cancer

Session Type: Oral Abstract Presentation

Title: Phase 3 prognostic analysis of the automated bone scan index (aBSI) in men with bone-metastatic castration-resistant prostate cancer (CRPC)

Location: Hall B1

Abstract No.: 5006



Date & Time: Monday, June 5, 2017, 1:15 PM-4:15 PM

Session Title: Genitourinary (Prostate) Cancer

Session Type: Poster Session

Title: Translating Prostate Cancer Working Group (PCWG) criteria into a quantitative progression biomarker in metastatic Castration Resistant Prostate Cancer (mCRPC)

Location: Hall A, Poster Board # 142

Abstract No.: 5068